The best way to stop Wegovy — what to expect and how to plan it

You've decided to stop, here's what's likely happening in your body right now

Picture this: you're on your final pen or thinking about stopping, and you're wondering whether the appetite suppression will just quietly fade or come back with a vengeance. That uncertainty is completely understandable. The honest answer sits somewhere between the two, and it depends partly on what you do next.

Semaglutide works by activating GLP-1 receptors that regulate hunger, slow gastric emptying and signal fullness to the brain. It does this continuously while the medicine is in your system. Once you stop, the drug clears gradually over several weeks (semaglutide has a long half-life of roughly a week) but when it has cleared, those hunger-suppressing signals stop too. The underlying biology that contributed to your weight in the first place does not change. The semaglutide treatment page describes this mechanism in more detail if you want the fuller picture.

What research consistently shows is that appetite tends to return, and weight tends to follow. A follow-up analysis from the STEP 1 trial, published in the New England Journal of Medicine, found that participants who stopped semaglutide regained roughly two-thirds of their lost weight within a year, and most cardiometabolic benefits also partially reversed. That is not a reason to panic, it is a reason to plan.

What a sensible stopping plan actually looks like

There is no official tapering schedule prescribed in the Wegovy licence, the Summary of Product Characteristics does not mandate a step-down dose sequence on stopping. Despite that, many prescribers prefer a gradual reduction from higher doses rather than stopping cold at 2.4mg or 1.7mg, because the jarring return of hunger at the top of the dose range tends to be harder to manage behaviourally.

The practical building blocks of a good exit plan look something like this. First, set a stopping date with your prescriber, not alone. They can consider your current dose, your weight history, any comorbidities, and whether a step-down makes clinical sense for you. Second, use the weeks before your last injection to reinforce the habits that have been quietly running alongside the medicine (protein-led meals, regular activity, structured meal timing) because these become your primary toolkit on the other side. The guide to losing weight on Wegovy covers the lifestyle elements worth locking in now.

Third, if you have been on Wegovy via the NHS, your specialist weight management team should be involved in this conversation; NICE's guidance on semaglutide (TA875) is built around multidisciplinary support, and that support matters most at stopping, not just starting. You can read the NICE appraisal of Wegovy for the full recommendation context. Fourth, be honest with yourself about the conditions under which you are stopping: planned and prepared is very different from frustrated and abrupt, and the outcomes usually reflect that difference.

The weight regain question, realistic expectations, not false reassurance

We want to be straight with you here, because vague reassurance does not serve anyone. Weight regain after stopping a GLP-1 medicine is common and well-documented. It is not a sign that you did something wrong or that treatment failed. Obesity is a chronic condition with strong biological drivers, and semaglutide works precisely because it counteracts some of those drivers pharmacologically. Remove the medicine and the drivers return.

What varies is how much regain happens and how quickly. People who have made durable changes to their eating patterns and physical activity during treatment tend to regain less, and more slowly, than those who relied entirely on the medicine's appetite effects. That gap in outcomes is the main argument for treating the stopping phase as an active process rather than just ceasing injections.

If stopping is financially motivated, it is worth knowing that Wegovy pricing varies considerably across private providers. The Wegovy cost breakdown explains what legitimate private treatment typically includes, because context around the full price, not just the headline figure, changes how people weigh the decision to continue or stop.

And if you are stopping because of side effects rather than choice, that is a different conversation to have with your prescriber, there may be options around dose, timing or supportive management that you have not yet tried. The guidance on taking semaglutide covers how injection technique and timing affect tolerability.

If stopping is temporary, pausing, switching or restarting

Sometimes stopping is not permanent. Travel, surgery, a pregnancy plan, a financial pause, there are plenty of reasons someone might stop Wegovy with the intention of restarting later. A few things are worth knowing in that case.

When restarting after a break of more than a few weeks, most prescribers will retitrate from a lower dose rather than resuming at the last-used dose. This is about tolerability: GI side effects that had settled during treatment can return when restarting at a higher level. Your prescriber makes that call based on how long the break was and what your current situation looks like.

If you are considering switching rather than stopping (for example, moving from Wegovy to tirzepatide) that is a clinical decision requiring a fresh assessment. The starting guidance is a useful reference for what the titration process looks like from the beginning. For anyone thinking about what a full private treatment pathway looks like, the treatment options page covers what our prescribers can assess you for.

One thing our prescribers hear often: people wish they had raised the 'I'm thinking of stopping' conversation earlier, rather than just stopping and dealing with the consequences. That conversation is exactly what a clinical review is for. If you want to talk it through, starting a free consultation is the easiest first step.